Abstract:LKB1 (liver kinase B1) is a master regulator of several processes such as metabolism, proliferation, cell polarity and immunity. About one third of non-small cell lung cancers (NSCLCs) present LKB1 alterations, which almost invariably lead to protein loss, resulting in the absence of a potential druggable target. In addition, LKB1-null tumors are very aggressive and resistant to chemotherapy, targeted therapies and immune checkpoint inhibitors (ICIs). In this review, we report and comment strategies that exploit peculiar co-vulnerabilities to effectively treat this subgroup of NSCLCs. LKB1 loss leads to an enhanced metabolic avidity, and treatments inducing metabolic stress were successful in inhibiting tumor growth in several preclinical models. Biguanides, by compromising mitochondria and reducing systemic glucose availability, and the glutaminase inhibitor telaglenastat (CB-839), inhibiting glutamate production and reducing carbon intermediates essential for TCA cycle progression, have provided the most interesting results and entered different clinical trials enrolling also LKB1-null NSCLC patients. Nutrient deprivation has been investigated as an alternative therapeutic intervention, giving rise to interesting results exploitable to design specific dietetic regimens able to counteract cancer progression. Other strategies aimed at targeting LKB1-null NSCLCs exploit its pivotal role in modulating cell proliferation and cell invasion. Several inhibitors of LKB1 downstream proteins, such as mTOR, MEK, ERK and SRK/FAK, resulted specifically active on LKB1-mutated preclinical models and, being molecules already in clinical experimentation, could be soon proposed as a specific therapy for these patients. In particular, the rational use in combination of these inhibitors represents a very promising strategy to prevent the activation of collateral pathways and possibly avoid the potential emergence of resistance to these drugs. LKB1-null phenotype has been correlated to ICIs resistance but several studies have already proposed the mechanisms involved and potential interventions. Interestingly, emerging data highlighted that LKB1 alterations represent positive determinants to the new KRAS specific inhibitors response in KRAS co-mutated NSCLCs. In conclusion, the absence of the target did not block the development of treatments able to hit LKB1-mutated NSCLCs acting on several fronts. This will give patients a concrete chance to finally benefit from an effective therapy.

LKB1 and lung cancer: more than the usual suspects

Putative Tumor-Suppressive Function of Krüppel-Like Factor 4 in Primary Lung Carcinoma

Identification of Key Genes and Evaluation of Clinical Outcomes in Lung Squamous Cell Carcinoma Using Integrated Bioinformatics Analysis

LKB1 and Cancer: the Dual Role of Metabolic Regulation.

LKB1 biology: assessing the therapeutic relevancy of LKB1 inhibitors

Expression Profiling of Ubiquitin-Related Genes in LKB1 Mutant Lung Adenocarcinoma.

Posttranslational regulation of liver kinase B1 in human cancer

LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers

Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α

LKB1: Can We Target an Hidden Target? Focus on NSCLC

The Tumor Suppressor Gene Lkb1 Is Associated With Prognosis In Human Breast Carcinoma

[Function and Prognostic Value of Tumor Suppressor Gene LKB1 in Human Breast Carcinoma].

Molecular chaperone complexes with antagonizing activities regulate stability and activity of the tumor suppressor LKB1

Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2

Advance of the research in the tumor suppressor gene LKB1

Integrative Genomic Analysis Reveals a High Frequency of LKB1 Genetic Alteration in Chinese Lung Adenocarcinomas.

Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer.

Dependency of human and murine LKB1-inactivated lung cancer on aberrant CRTC-CREB activation

LKB1 Mutations Enhance Radiosensitivity in Non-Small Cell Lung Cancer Cells by Inducing G2/M Cell Cycle Phase Arrest

Abstract 348: LKB1 Deficiency Confers Lung Adenocarcinoma Phenotypic Plasticity with Squamous Transdifferentiation Potential.

Enhanced Expression of LKB1 in Breast Cancer Cells Attenuates Angiogenesis, Invasion, and Metastatic Potential